David Sinclair is probably the single most publicly visible ageing researcher alive, and also one of the most contested within his own field. Both things are true at once, and a genuinely academic look at his work has to hold them together rather than picking a side. Here is his actual research, properly referenced back to the primary papers, the serious scientific pushback it has received, and where to hear him explain all of it in his own words.

Who he actually is

David A. Sinclair, AO, PhD, is a tenured Professor in the Department of Genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research there. He completed his PhD in molecular genetics at the University of New South Wales in Sydney in 1995 before a postdoctoral position at MIT, and has published well over 200 peer-reviewed papers and is a named co-inventor on more than 50 patents. He is the author of the New York Times bestseller Lifespan: Why We Age and Why We Don’t Have To, and co-founded several biotechnology companies working on ageing, four of which have since gone public. None of this makes his specific scientific claims automatically correct, credentials establish standing to be taken seriously, not immunity from scrutiny, but it does mean any fair review of his work needs to engage with the actual research rather than either dismissing or lionising the public persona.

The core idea: the Information Theory of Ageing

Sinclair’s central theoretical claim is that ageing is not solely the accumulation of genetic mutations or molecular damage, the dominant view for decades, but substantially the progressive loss of epigenetic information, the chemical instructions layered on top of DNA that tell a cell what type of cell it is and what genes to switch on or off. Under this model, cells do not forget how to be young because their underlying DNA “hardware” is destroyed, but because the epigenetic “software” running on top of it becomes corrupted with age, in principle a more reversible problem than genetic mutation. This is a genuinely significant reframing if correct, and it is the theoretical basis behind most of the specific experimental work described below. It remains, honestly, a contested and still-developing framework within the wider ageing research field, not a settled consensus.

The foundational discovery: sirtuins and resveratrol

Sinclair’s rise to prominence began with a 2003 paper in Nature, identifying resveratrol, a polyphenol compound found in the skin of red grapes and in red wine, as a small-molecule activator of sirtuins, a family of proteins linked to the lifespan-extending effects of calorie restriction, and showing that it extended the replicative lifespan of yeast. The discovery led directly to Sinclair co-founding Sirtris Pharmaceuticals, acquired by GlaxoSmithKline for $720 million in 2008 specifically to develop sirtuin-activating drugs.

What followed is an important and honestly under-told part of the story. Other laboratories, including a widely cited 2013 analysis from a team at Amgen, argued that the original assay used to demonstrate resveratrol’s direct activation of SIRT1 produced a fluorescence artefact rather than a genuine biochemical effect, and that resveratrol does not directly activate SIRT1 in the way first proposed. Separately, GSK halted development of its lead resveratrol drug candidate, SRT501, in 2010 after a clinical trial in multiple myeloma patients raised kidney-safety concerns, and eventually wound down the Sirtris programme entirely. Sinclair has publicly defended the underlying resveratrol research and has continued to take it himself; the assay-artefact critique remains a genuine, unresolved point of scientific contention rather than a fully settled refutation. Either way, resveratrol’s journey from Nature paper to $720 million acquisition to halted clinical trial is a genuinely instructive case study in how far preliminary molecular findings can travel before the harder clinical evidence catches up, or fails to.

NAD+, sirtuins and NMN

The Sinclair lab was among the first to identify a role for NAD+ biosynthesis in regulating lifespan in laboratory models, and to show that sirtuins contribute to the benefits of calorie restriction in mammals specifically. This line of work underpins the now-widespread interest in NAD+ precursor supplements such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), on the theory that restoring falling NAD+ levels with age might restore some of sirtuins’ protective activity. It is worth being precise about what currently exists here: solid, published mechanistic and animal-model research establishing NAD+’s role in these pathways, and a considerably thinner body of large, long-term, placebo-controlled human trials demonstrating that NMN supplementation itself extends healthy human lifespan. The mechanism is well studied. The specific human longevity claim built on top of it, the one most heavily marketed by the wider supplement industry, is not yet proven at anything like the same standard.

The most striking recent work: reversing vision loss in mice

Arguably the single most scientifically significant paper from the Sinclair lab is a 2020 study published in Nature, using a partial set of the Yamanaka reprogramming factors, Oct4, Sox2 and Klf4 (OSK), delivered via gene therapy to retinal ganglion cells in mice. The treatment restored more youthful DNA methylation patterns, promoted nerve regeneration after injury, and reversed vision loss in both aged mice and a mouse model of glaucoma. This work is genuinely well regarded within the ageing research field, published in one of the most rigorously peer-reviewed journals in science, and represents a real proof of concept that at least some age-related cellular damage can be reversed rather than merely slowed. It is, importantly, a result in mouse retinal cells specifically, not yet a demonstrated whole-body human anti-ageing treatment, and translating gene-therapy reprogramming safely into humans at scale remains a substantial unsolved problem.

The scientific pushback, presented fairly

Sinclair’s work, and the broader sirtuin field he helped establish, has faced serious, credentialled scientific criticism, not merely internet scepticism. A prominent 2022 paper by biochemist Charles Brenner, published in the journal Life Metabolism and titled bluntly “Sirtuins are not conserved longevity genes,” argued that the original yeast findings underpinning the sirtuin-longevity link do not hold up as well as widely assumed, that some early positive results were reported before problems with the underlying assays were fully understood, and that review articles have since propagated that early, weaker evidence more confidently than it deserves. This is a genuine, ongoing scientific dispute within a legitimate field of research, not a fringe objection, and a properly academic treatment of Sinclair’s work has to include it rather than presenting the sirtuin story as uncontested.

What he actually suggests you can do

Separate from the laboratory research itself, Sinclair has been consistently public, across his book and numerous interviews, about his own personal daily practice, and it is worth being clear that this is self-reported personal habit, not itself a clinical trial result, and some elements require medical supervision. Publicly and repeatedly reported components include: a compressed daily eating window with breakfast typically skipped, aiming for roughly 14 to 16 hours without food most days; a combination of zone 2 (steady, moderate-intensity) cardiovascular exercise and resistance training; regular cold exposure, including cold showers, as a mild hormetic stressor; close attention to sleep; and a personal supplement stack that has included NMN, resveratrol (taken with a small amount of fat for absorption), vitamin D3 with K2, and, at various points, metformin, a prescription diabetes medication he has described taking off-label, which is not something to replicate without a doctor’s involvement. He has also been open that this stack has evolved over time as his own reading of the evidence has changed, which is itself a reasonable, if unusual, level of public transparency for a public figure in this space.

Hear him explain it himself

For anyone who wants Sinclair’s own account of this research, in his own words and with time to actually explain the nuance, his appearance on The Diary of a CEO with Steven Bartlett is a substantial, direct primary source, covering the Information Theory of Ageing, the reprogramming work, and his personal protocol at length.

Listen to the full Diary of a CEO episode with David Sinclair

His academic record, direct from the source

For anyone who wants to go beyond secondary coverage, his primary academic profiles are the most reliable way to see the actual, current body of work rather than any single summarised version of it.

What this is not

This is not medical advice, and none of the specific practices Sinclair reports, particularly extended fasting, cold exposure, or any prescription medication, are appropriate for everyone without individual medical guidance. It is also not a verdict. The honest, academic position on David Sinclair’s body of work, taken as a whole, is that it contains genuinely significant, well-published, peer-reviewed science, alongside commercial ventures and public claims that have moved considerably faster than the underlying clinical evidence, and a live, credible scientific debate about how solid the foundational sirtuin theory actually is. Holding all three of those facts at once is the only intellectually honest way to engage with it.

Frequently asked questions

Does taking resveratrol actually slow ageing in humans?

This has not been demonstrated in large, long-term human trials. The original laboratory findings extended lifespan in yeast and showed resveratrol activating sirtuins in cell-based assays, but subsequent research questioned whether that activation was a genuine biochemical effect or an artefact of the test method, and a major clinical programme built on a resveratrol drug was halted after a safety signal, not a demonstrated anti-ageing benefit, emerged in trial patients.

Is NMN proven to extend human lifespan?

No, not yet, at the standard that word implies. The underlying science, NAD+ decline with age and its role in sirtuin activity, is genuinely well studied in laboratory models. Large-scale, long-term, placebo-controlled human trials specifically demonstrating that NMN supplementation extends healthy human lifespan do not yet exist, which is a meaningfully different claim from the mechanism being real.

Has anyone actually reversed ageing in a living animal?

In a specific, published sense, yes. Sinclair’s 2020 Nature paper used partial reprogramming factors delivered by gene therapy to restore youthful gene-expression patterns and reverse vision loss in the eyes of aged and glaucomatous mice. That is a genuine, peer-reviewed result. It is a result in mouse eye tissue using a targeted gene therapy, not a demonstrated whole-body human anti-ageing treatment, and the distance between the two remains considerable.

What is the Information Theory of Ageing, in plain terms?

It is Sinclair’s proposal that ageing results largely from a progressive loss of epigenetic information, the chemical instructions that tell a cell what kind of cell to be, rather than solely from irreversible damage to the DNA sequence itself. If broadly correct, it implies ageing could in principle be more reversible than the traditional damage-accumulation model suggests, since the underlying genetic “hardware” is not itself destroyed. It remains an actively debated theoretical framework rather than settled scientific consensus.

Should I take the same supplements David Sinclair takes?

Not without your own doctor’s involvement, and not on the assumption that his personal, self-reported regimen constitutes clinical proof of anything. His stack has included a prescription medication used off-label, has changed over time as his own view of the evidence evolved, and reflects one individual’s personal risk tolerance rather than an evidence-based clinical protocol validated for the general population.

Is David Sinclair a credible scientist, given the controversy?

He is a genuinely credentialled, highly published Harvard geneticist whose laboratory has produced real, peer-reviewed, significant findings, and he is also a public figure and commercial entrepreneur whose public claims and business ventures have, at points, moved faster than the underlying clinical evidence, and whose foundational sirtuin research has drawn serious, credentialled scientific criticism from other researchers in the same field. Both of those things are true simultaneously, and a fair assessment holds both rather than resolving into a simple yes or no.

References

  • Howitz, K.T., Bitterman, K.J., Cohen, H.Y. et al. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 425, 191-196. nature01960
  • Lu, Y., Brommer, B., Tian, X. et al. (2020). Reprogramming to recover youthful epigenetic information and restore vision. Nature, 588, 124-129. doi:10.1038/s41586-020-2975-4
  • Brenner, C. (2022). Sirtuins are not conserved longevity genes. Life Metabolism, 1(2), 122-133. Oxford Academic
  • Sinclair, D.A. with LaPlante, M.D. (2019). Lifespan: Why We Age and Why We Don’t Have To. Atria Books.